Understanding cultural barriers in hepatitis B virus infection.

Geffen UCLA School of Medicine, Center for Liver Disease and Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cleveland Clinic Journal of Medicine (Impact Factor: 3.37). 06/2009; 76 Suppl 3(Suppl_3):S10-3. DOI: 10.3949/ccjm.76.s3.03
Source: PubMed

ABSTRACT The prevalence of hepatitis B virus (HBV) infection in the Asian American population is disproportionately high compared with the US population as a whole. Effective management is difficult because of cultural barriers, which can be better understood with recognition of the diversity of the Asian continent in terms of language and spiritual beliefs. Barriers to care among the Asian American population include educational deficits, low socioeconomic status, lack of health insurance, noncitizenship, inability to communicate in English, negative perceptions of Western medicine, and underrepresentation among health care professionals. Given the diversity of the population, some subpopulations may be more directly affected by certain barriers than others. The resulting delays in seeking care can lead to poor outcomes and risk of HBV transmission to household members. Health care providers are obligated to educate themselves regarding cultural sensitivity and to advocate for improved access to care.

  • Source
    01/2012; Australian Research Centre in Sex, Health and Society, La Trobe University., ISBN: 9781921915123
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current estimates suggest over 218,000 individuals in Australia are chronically infected with hepatitis B virus. The majority of these people are migrants and refugees born in hepatitis B endemic countries, where attitudes towards health, levels of education, and English proficiency can be a barrier to accessing the Australian health care system, and best managing chronic hepatitis B. This study aimed to assess the knowledge of transmission and consequences of chronic hepatitis B among these patients.
    BMC Infectious Diseases 10/2014; 14(1):537. DOI:10.1186/1471-2334-14-537 · 2.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B remains a global health issue, despite an effective vaccine. Mother to child transmission (MTCT) of hepatitis B has become increasingly recognized, especially in those patients with high maternal viremia. In a woman of childbearing age, carefully assessing disease status and urgency of treatment is key, along with discussion of family planning, timing and choice of therapy. In a pregnant patient with chronic hepatitis B, treatment in the third trimester may be considered in those with HBV DNA levels >107 copies (2 × 106 IU/ml) and may reduce the perinatal transmission rate, but a thorough discussion of the risks and benefits is essential. Duration of antiviral therapy depends upon the indication for treatment as those individuals treated for active disease from the hepatitis B would need long term therapy, while those treated in the third trimester only to prevent MTCT may have therapy discontinued.
    Current Hepatitis Reports 03/2013; 12(1). DOI:10.1007/s11901-012-0154-2